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                                               Karin Braide, MD 
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                                                              ABSTRACT 
We analyzed side-effects, pre-treatment bladder preparations and dose distribution to 
the rectum in four different cohorts of patients, treated with postoperative 
radiotherapy (PRT) in prostate cancer. 
Side-effects according to a self-reporting survey revealed rectal bleeding as a main 
result in a follow up time of 6.7 years in median, since PRT, compared to a control 
group of men only treated with surgery only. Side-effects from the urinary tract was 
less pronounced between the groups and no difference was found according to sexual 
function or global quality of life (Paper I). Further analysis of rectal bleeding and its 
relationship to rectal dose volume parameters was performed and compared to a new 
treatment technique in order to develop a risk assessment method. We identified dose 
response relationships between rectal dose distribution and reported rectal bleeding 
which could be applied to a newer treatment technique in order to better evaluate the 
dose volume parameters and calculated risk of rectal bleeding (Paper II).                                                                                                                                       
A register based nationwide cohort study, of men prostatectomized between 1997 
and 2016 was performed with focus on those men that had PRT added to the prior 
surgery. A comparison was made between the two groups focusing on severe side-
effects that had been surgically handled. Interventions in the urinary and rectal tract 
were analyzed as were development of secondary malignancies and compared 
between the groups. Dominating were surgical interventions in the urinary tract in the 
PRT group with 3.66 higher risk per person year compared to the RP only group. The 
risk of development of bladder cancer was more than twice as big in the PRT group 
(Paper III). In a prospective clinical trial two different bladder preparation protocols 
were evaluated in men going through PRT. We could not detect any difference 
between the protocols according to bladder filling compliance or target localization 
(Paper IV). 
Conclusion: this work has brought new insights on the development of late side 
effects in PRT and revealed areas of possible improvements in the practical work at 
the radio- therapy department. 
Keywords: prostate cancer, postoperative radiation therapy, side-effects, practical 
preparations 
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 SAMMANFATTNING PÅ SVENSKA 
Prostatacancer är den vanligaste cancerformen i Sverige med ca 10 500 nya fall 2019 
och operation, radikal prostatektomi, RP, utfördes då på 2100 män. Postoperativ 
strålbehandling, PRT, ges då det finns tecken till återfall i sjukdomen med stigande 
prostata specifikt antigen, PSAvärde. Med syfte att förbättra PRT, som ges 35 gånger 
under en sju veckors period, ville vi studera förekomst av biverkningar, på längre 
sikt, och det praktiska genomförandet på strålavdelningen. Biverkningar efter PRT 
utvärderades och jämfördes med män som bara genomgått RP, dels via en 
självskattningsenkät (artikel 1) och dels via analyser från en rikstäckande databas, 
PCBaSe. Enkätsvaren visade att patienterna i PRT-gruppen i större utsträckning 
besvärades av blödning från ändtarmen jämfört kontrollgruppen som bara hade 
genomgått RP, vid en uppföljningstid på 6.7 år i median. Vi såg också i enkätsvaren 
att tillägg med PRT inte, i någon större utsträckning, påverkade kontinensen eller den 
sexuella funktionen jämfört med RP gruppen. Som följd av de rapporterade 
ändtarmsblödningarna gjorde vi en beräkning, via stråldosplaneringsdata, av 
relationen mellan blödning och hur stor stråldos som hamnat i ändtarmen (artikel 2). 
Vi kunde via denna analys skapa ett riskvärderingsverktyg för uppkomst av 
ändtarmsblödning att använda vid planering av kommande strålbehandling. PCBaSe 
är en patient-databas där flera register från hälso-och-sjukvården ingår förutom den 
registrering som görs av alla med prostatacancer i Sverige, Nationella Prostata 
Cancer Registret, NPCR. Med syfte att utvärdera hur behandlingen med PRT 
påverkar behovet av kirurgisk behandling, i ett långtidsperspektiv analyserades data 
från PCBaSe (artikel 3). Vi fann att risken att behöva genomgå operativt ingrepp i 
urinvägarna var större hos de i PRT gruppen än kontrollgruppen under en maximal 
uppföljningstid på 15 år. Vad gäller operationer i ändtarmsregionen kunde vi inte 
påvisa några egentliga skillnader mellan grupperna. Vi värderade också risken att 
utveckla sekundär cancer i urinblåsan och fann den ökad men inte cancer i 
ändtarmen, för PRT gruppen. Slutligen värderades dödsorsaker i grupperna; risken 
att avlida i prostatacancer var avsevärt ökad i PRT gruppen men risk att avlida av 
annan orsak var jämförbar i de båda grupperna.  
Förberedelse för strålbehandling sker med rekommendationer om att urinblåsan ska 
vara lika fylld vid alla behandlingstillfällena. Vi jämförde två förberedelseregimer för 
att se om urinblåsan kunde bibehålla samma fyllnad inför behandlingarna under hela 
behandlingstiden. Vi kunde inte påvisa någon skillnad mellan de två grupperna; stora 
variationer i blåsfyllnad förelåg för enskilda patienter, mellan patienter och mellan 
grupperna då volymerna mättes (artikel 4). 
Sammanfattningsvis har vi kartlagt förekomst av sena biverkningar, både 
patientrapporterade och via register, och funnit förbättringspotential vid 
genomförandet av strålbehandlingen för män som behandlas med PRT. 
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1 INTRODUCTION 
The author’s reflections 
After many years of clinical work in the treatment of men suffering 
from different stages of prostate cancer (PC), introduction of 
postoperative radiotherapy (PRT) was a challenge for me. In short, it 
was necessary to change from dealing with surgery and often visible 
and touchable structures to performing image-based handling of 
patients with an “invisible” disease identified solely by an elevated 
level of prostate-specific antigen (PSA). In the clinical setting, this 
meant that informing a worried man and his partner about the 
possibility of a cure and potential side effects of treatment became a 
difficult task that could not always be based on reliable facts. The 
practical work in the radiation department involved knowing how to 
prepare for, perform, and follow the 7-week-long treatment, which 
would have an impact on both the possibility of cured and the 
development of side effects. 
 
The questions regarding my uncertainties were many, and I am very 
grateful for having had the opportunity to conduct research of true 
clinical value. In short, I have addressed the following issues in my 
studies: 
How can we prepare the organs that are close to and/or part of the 
treatment target, namely the urinary bladder and the rectum, which 
normally vary in volume and location? 
What side effects can be expected to occur and to what extent in both 
the short and the long term in our own clinic? 
In what manner can the treatment procedure be followed so as to 
ensure correct delivery? 
 
These are some of the questions I considered in the work leading to 
this thesis, but there are many aspects that remain to be elucidated.  
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The patient’s concerns 
The patient’s perspective is of great importance in the context of 
treatment information and decision-making, and this aspect should be 
in consensus with the patient himself. To achieve this, it is necessary to 
capture the doubts and anguish that a man in the relapse situation is 
experiencing, after initially believing that he has been cured by 
prostate surgery and later finding himself menaced by potentially life-
threatening disease indicated by a rising PSA. In this situation, all 
possibilities to be cured appear to be the correct choice to make, even 
though the chance of cure is minimal [1]. The patient’s longing for 
some new curative treatment option is strong, and this should be kept 
in mind by the doctor when discussing treatment options with the 
patient. The doctor’s role is to provide balanced information on the 
planned procedure, which also includes considering whether to refrain 
from treatment. In 2017, Shakespeare et al. [2] reported that patients 
who were asked about their satisfaction after radical prostatectomy 
(RP) combined with PRT described a degree of regret that was not 
negligible. The main reason for the regret was the level of side effects, 
and it was expressed by about 17% of the patients in that study during 
a median follow-up period of 78 months, even though freedom from 
disease was 70% in that group. This observation stresses that it is 
important that the patient should be given information that is based on 
both scientific and experiential knowledge in relation to the patient’s 
own situation, including good awareness of the potential side effects 
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Diagnostic procedure 
The PSA limits that are set vary with age and are considered to be 
elevated [6] when the following applies: 
 
Age, years PSA ng/ml 
< 70 ³ 3 
70–80 ³ 5 
> 80 ³ 7 
 
In addition to a PSA test, the diagnostic procedure includes rectal 
examination to judge the extent of the cancer; T staging, and 
transrectal ultrasound (TRUS) combined with core biopsies if deemed 
reasonable. Starting in 2020, the Swedish Prostate Care Program 
(www.cancercenrtrum.se) recommends that magnetic resonance 
tomography (MRT) should be performed before the TRUS 
examination and biopsies to reduce the number of biopsies necessary 
as much as possible and thereby avoid the risk of overdiagnosis and 
infection[7]. 
 
Risk classification is based on the histological findings from biopsies, 
together with TNM classification, which comprises the following: T, 
local tumor extension; N, regional nodal extension; and M, distant 
metastases. Complementary radiographic investigations are added in      
cases with high-risk parameters to be able to exclude the presence of 
nodal extension and metastases.     
 
 
Risk classification 
PC is divided into three risk categories designated low, intermediate,          
high and advanced disease, when there is supplementary information 
on finding of metastasis. This classification is based on PSA level, 
clinical palpation with T staging and pathoanatomical findings after 
biopsy, with Gleason grading [8]. 
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Risk categories  PSA ng/ml T stage Gleason score 
Low  < 10  T1–T2a ³ 6 
Intermediate  10–19.9 and/or  T2b    and/or    ³ 7 
High  > 20   and/or  T2c-T3 and/or  ³ 8 
 
In short, the high-risk group is advocated treatment with curative 
intent, and the low-risk group should be followed with preparedness to 
treat curatively and active surveillance. In most cases, the intermediate 
group can be handled with expectancy or by treatment with curative 
intent, depending on the patient’s preference and additional clinical 
factors. Men with metastasis are recommended hormonal treatment 
and in some cases complementary primary treatment, because novel 
results in the literature have shown improved survival when applying 
such an approach in these patients [9]. 
 
Treatment with curative intent can be achieved through surgery (RP) 
or through radiotherapy (RT) with or without hormonal treatment. Of 
the 10,000 men diagnosed with PC in Sweden in 2018, 50% were 
offered treatment with curative intent, and approximately 2,500 
underwent RP. Complementary RT treatment after surgery has been 
developed to enable cure in the majority of men with PSA relapse of 
the disease. To irradiate the postoperative fossa, where the prostate 
was located before RP, has become a standard approach, although it 
has only been in practical use since 2000 at Sahlgrenska University 
Hospital. In 2018, about 650 men in Sweden received PRT. 
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History of surgical treatment   
In 1867 in Vienna, Austria, Theodor Billroth apparently performed the 
first planned surgical removal of PC as a partial perineal excision. In 
1904 in Baltimore, Maryland, in the United States, Hugh H. Young 
(1870–1945) carried out the first perineal RP and published a report 
on184 patients he had treated in that manner[10]. Early in the 1900s in 
France, Robert Proust, brother of the famous author Marcel Proust, 
was described as a promotor of the perineal approach in prostatectomy, 
which was consequently named “Proustatectomy” at that time. Proust’s 
doctoral thesis entitled “Prostatectomie perineale totale” was 
published in 1900 (see Figure 1).         
 
  
Figure 1 An illustration of Robert Proust’s surgical arrangement with perineal 
approach in prostatectomy from his thesis entitled “Prostatectomie perineale totale” 
published in 1900 (available from AbeBooks.com). 
Further development of surgical techniques was later achieved by 
Terence Millin [11], who published the first series of retropubic 
prostatectomies in 1945, and the sacroperineal approach was 
introduced by Thiermann in 1952. In 1991, another new era in prostate 
surgery began with the first laparoscopic prostatectomy, and further 
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development introduced the robotic approach first reported 2000. In 
2011 Binder presented the laparoscopic DaVinci prostatectomy. 
 
 
Figure 2 The Da Vinci surgery system, around 2010 
 
Radical prostatectomy 
The surgery for localized PC is RP, which can be performed either as 
an open procedure called retropubic prostatectomy (RRP) or as a 
laparoscopic event that is now often robot assisted (called robot-
assisted radical prostatectomy [RALP] see Figure 2). Short term side 
effects in RRP are described as perioperative bleeding, infection and 
injuries to the intestine and in the long-term perspective incontinence, 
erectile dysfunction and development of anastomotic strictures. For 
short-term outcomes, advantages of RALP over RRP, for example, 
regarding blood loss and length of hospital stay, have been reported by 
the Swedish LAPPRO (Laparoscopic Prostatectomy Robot or Open 
Trial) group [12]. Functional outcomes with respect to side effects are 
primarily related to aspects of continence and erectile function, but can 
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also include strictures in the bladder neck[13]. The functional results of 
RP depend mainly on the extent of cancer in the prostate and the 
surgeon’s experience [14,15]. Studies have provided divergent data on 
long-term functional outcomes. In a metanalysis published in 2012, 
Ficarra et al. found that, compared to RRP, RALP offered better 
urinary continence recovery at 12 months after the surgery. In 2018, 
Nyberg et al. [16] described better patient-reported outcome in erectile 
function with RALP than with RRP at 24-month follow-up, but no 
difference between the two approaches regarding continence. Further 
follow-up and analysis data are to be expected from the LAPPRO 
group. Oncological results have shown that 25–40% of men treated 
with RP develop a biochemical (i.e., PSA) relapse or are not cured 
initially [17,18]. In the relapse situation, complementary treatment is 
advocated, and the only possible curative treatment available today is  
PRT, which will be discussed below.  
 
At Sahlgrenska University Hospital, RALP has become the method of 
choice, and, with very few exceptions, essentially all curative-intent 
surgeries for PC are performed with this approach. In most cases, the 
patient is admitted to the hospital the morning of the surgery and is 
discharged the following day if there are no complications. A catheter 
is placed in the bladder and removed 7 days later as an outpatient 
procedure. The PSA value is then monitored for 10 years with attempt 
to trace an increasing value. 
 
 
 
Postoperative radiation therapy 
RT as a treatment modality after surgical removal of a diseased organ, 
with curative intent, is practiced not only in PC but in many other 
forms of cancer as well, such as head and neck and breast cancer. In 
those cases, the RT is delivered in direct connection with the surgery 
that is performed, whereas in PC the RT can be administered at the 
time of PSA relapse. The era of PSA exploitation changed PRT in PC, 
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and, in the early 1990s, Ward et al. [19] referred to a detectable 
biochemical recurrence as a “paradigm”. Before that time, in the 
1980s, when a positive margin or positive lymph nodes were found at 
surgical exploration  RT could be delivered as a complement [20]. 
However, both the side effects and the results of that approach were 
unfavorable, and hence such treatment was abandoned. 
With the advent of PSA sampling, it became possible to detect an early 
relapse of PC after the primary surgery and plan a supplementary 
treatment with curative intent de novo. Nonetheless, it was not until 
2005 that reports and prospective data on this treatment were presented 
by the European Organization for Research and Treatment of Cancer 
(EORTC) study 22911 [21]. 
In Sweden in 2018, PRT was given to 650 patients according to 
guidelines and consensus, but this number is considered too low when 
taking the number of surgeries performed into account [22]. PRT is 
carried out as either adjuvant RT (ART) or salvage RT (SRT), the 
latter of which is applied when there is a biochemical relapse. As in 
other forms of cancer mentioned above, ART is a complementary 
treatment that is conducted after surgery when the postoperative 
histology findings are unfavorable, and it is often administered at a 
lower dose. The question of which treatment offers the best outcome 
according to oncological results, survival, and side effects has been 
focused on and studied prospectively for the last 15 years by 
prestigious expertise with somewhat varying results [23-25]. In a 
recent metanalysis of three randomized prospective studies comparing 
ART and SRT (RADICALS, GETUG-AFU 17, and RAVES) [26], it 
was suggested that these two RT treatment options offer similar 
outcomes of event-free survival. However, adopting SRT instead of 
ART can in many cases prevent unnecessary RT with associated side 
effects. In this treatment setting, to administer RT at the lowest level 
possible when there is an increase in PSA would result in a favorable 
outcome with regard to side effects and a 5-year PSA-progression-free 
probability of > 85%. SRT has already been the recommended strategy 
in Sweden over the last years. 
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Hormonal treatment 
Hormonal treatment of PC was first used in the 1890s to reduce the 
symptoms of prostatic hypertrophy. C. B. Huggins performed 
experimental studies on prostate tissue and demonstrated the 
association between testosterone and secretion from prostatic cells and 
the reciprocal effect of estrogens, and, for these findings, Huggins was 
awarded the Nobel Prize in Physiology or Medicine in 1966. He later 
also proved that castration relieved pain from skeletal metastases in PC 
patients [27]. 
 
Hormonal therapy is an obvious strategy in PC and was long the only 
treatment offered to men with incurable or metastatic disease. Up until 
the 1990s, the hormonal treatment was achieved by surgical castration, 
that is, removal of the testicles. Today, the dominating hormonal 
approach is pharmacological in the form of androgen deprivation 
therapy (ADT), and this can be performed in two different ways: as a 
blockade of the androgen receptor; or as a pharmacological castration 
mediated via the pituitary hormones LH and FSH, which results in 
inhibition of the synthesis of testosterone. The side effects of such 
castration treatment can be numerous and severe, and, in addition to 
sexual dysfunction, include osteoporosis, metabolic syndrome, 
flushing and sweating, and weight gain [28]. 
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RADIOTHERAPY 
History of radiotherapy                                                                       
The history of RT dates back to when Conrad Röntgen discovered x-
rays in 1895, and when Henri Becquerel detected natural radiation 
from the element uranium in 1896. These two men won the Nobel 
Prize in Physics in 1901 and 1903, respectively. Marie Curie also 
studied radioactivity and won a Nobel Prize twice: first in physics 
in1903 together with Henri Becquerel and her husband Pierre Curie for 
studies on the phenomenon of radiation; and the second time in 
chemistry in 1911 on her own for discovering the elements radium 
(1898) and polonium. (“The Discovery of Radium” by Marie Curie is 
available as an E-book at www.project Gutenberg.de.) Radium has 
been used extensively in the development of RT, initially mainly as 
external applicators in skin cancer. Use of radiation energy in medicine 
was tailored to fit different scenarios [29]. For instance, local treatment 
of the prostate through a cystoscopic radium applicator was performed 
in the 1910s, and this probably represents the birth of brachytherapy 
for PC, a treatment option that is widely applied today[30]. External 
beam therapy for PC was not initiated until the 1960s, even though this 
treatment was performed for the first time in 1904. In the 1920s and 
1930s, PRT was discussed pragmatically as a complement to 
unsuccessful surgical procedures for PC, but the outcome in that 
context was not particularly successful [19]. 
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Target, treatment planning, and treatment techniques 
 
The target in general 
Delivery of RT requires careful treatment planning before initiating the 
treatment to indicate where and how the irradiation should be carried 
out. A target is outlined based on radiological images obtained by a 
planning computerized tomography, pCT and MRT. Of those two 
techniques, MRT is superior in visualizing the appearance of soft 
tissue, which constitutes the target in PRT. The MRT and CT 
examinations constitute the basis of the treatment planning and are 
performed a few weeks before treatment start. The target delineation is 
also based on the surgery specimen report, which provides information 
on tumor extension and surgical margins, and target guidelines 
developed from clinical experience that together result in a clinical 
target volume (CTV). Hence the CTV represents the volume where the 
cancer cells are, or are assumed to be, located. Furthermore, a margin 
is added to the CTV that is intended to guarantee the uncertainties that 
can occur when the patient is in the treatment position (e.g., internal 
movement and set-up errors), and this constitutes the planning target 
volume (PTV). 
 
Treatment planning 
Based on the CTV/PTV, a planning of radiation treatment is 
constructed by using a computerized treatment planning system that 
can visualize the distribution of the radiation dose. The radiation dose 
will be delivered to a volume in three dimensions, and it is possible to 
calculate the dose given to any specific point in the patient. The 
evaluation of the 3D dose distribution is usually carried out using a 
dose-volume histogram (DVH), which graphically summarizes the 
dose distribution in the CTV, PTV, and organs at risk (OaR) volumes 
(see Figure 3). Together with the DVH, treatment recommendations 
are provided concerning how percentages of the different volumes 
should be covered by the prescribed dose and to what limits the OaR 
can be exposed to the radiation. The goal of the treatment plan 
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optimization is to ensure that the CTV mean dose is 100% of the 
intended dose delivered to the target, and that the OaR are spared as 
much as possible. 
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radiographs (DRRs) created from the pCT in the treatment plan. The 
matching is accomplished towards skeletal structures since soft tissue, 
as the bladder and rectum, not are visible on a radiograph. Other 
examples of matching procedures are through a cone beam CT 
(CBCT), which represents a version of a CT (covering large volume 
with one single rotation about the patient) [31] and with this method 
soft tissue is visible and possible to match to in the PRT session.  
In treatment of primary PC, the matching procedure is performed using 
markers, often consisting of gold, which are deposited in the prostate 
and can be reproduced in a radiograph/X-ray and thus make it possible 
to achieve a most acceptable fit. In the postoperative setting, there is 
no clear organ of choice in which markers can be placed, although the 
surgical clips that are inserted during the surgical procedure are used as 
markers in some cases [32] and a procedure to insert radiopaque tissue 
fiducial markers is described[33]. The urinary bladder and rectum  can 
be implemented as matching structures, not by radiographs but by 
verifying their position in a CBCT, in which those organs can be 
visualized with respect to both volume and location [34]. The use of 
CBCT in the matching procedure for PRT is gaining ground as an 
obvious choice to achieve a better outcome. 
 
Treatment techniques 
In 2001, SRT was performed on a few patients at Sahlgrenska 
University Hospital, and this was initially done by three-dimensional 
conformal radiotherapy (3DCRT). Further development of the 
technology has resulted in improvements in the delivery of RT by what 
is called intensity-modulated RT (IMRT), and the rotation arc method 
designated volumetric modulated arc therapy (VMAT), which is now 
fully implemented at many radiation departments, including ours. With 
the VMAT technique, the radiation dose distribution can be better 
shaped according to the PTV and consequently has the potential to 
spare the OaR to a greater extent (see Figure 4). The duration of 
delivering the treatment is also shorter with VMAT, which is an 
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advantage to minimize organ motion, both in externa and internal 
respect. 
 
 
 
Figure 4 A SRT patient’s VMAT plan with dose distribution, “color wash” 
representing dose levels of 35 to 70Gy. This VMAT plan was made for PRT treatment 
and on the same patients images a 3DCRT plan was constructed.  
 
Dose prescription 
The radiation dose to the postoperative area can vary, but the Swedish 
Care Program recommends a prescription dose of 70 Gray (Gy) in total 
for SRT, delivered at 2 Gy per treatment fraction, thus resulting in 35 
days of treatment in a 5-days a week schedule. In ART, the prescribed 
dose is lower, often 66 Gy in 2-Gy fractions. Further development of 
SRT in the future will probably include evaluating the concept of 
hypofractionation, which entails a larger dose per fraction and 
consequently fewer treatment days. There are a few reports on this 
topic, and thus additional assessments are needed before 
hypofractionation can be implemented in the clinical setting [35,36]. 
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Mechanism of action 
The goal of cancer treatment is to kill, cancer cells by damaging their 
DNA, and that can be accomplished with ionizing radiation. This 
action is mediated through radiolysis of water, which is abundant in 
living cells, and it produces free radicals that impair the DNA. The 
ionizing rays are also deleterious to the normal tissue, but the cells in 
such tissue have the ability to repair DNA, and this is a fundamental 
difference compared to cancer cells. In short, this means that the 
radiation beams must be modulated in a balanced way so that cancer 
cells can be destroyed while normal cells stay intact, or at least suffer 
as little damage as possible. This is the background to the concept of 
fractionation in RT (see Figure 5). The normal tissues in the area 
receiving PRT are located predominantly in the urinary bladder, the 
rectum, and nerves involved in the erectile process, and the described 
side effects arise from those sites. 
 
 
Figure 5 Graph illustrating on fractionated radiotherapy with normal tissue 
tolerance and cancer cell death. 
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DECISION-MAKING IN SRT 
 
Offering a man SRT at PSA relapse means offering him a second 
chance to be cured. In many studies clinicians have found that the PSA 
limit of 0.2 ng/ml is optimal [18] and that a worse outcome can be 
expected at values above that level. However, values between 0.03 and 
0.5 have also been described as optimal in the literature [37,38]. No 
other treatment known today can provide the possibility of cure. 
Therefore, the recommendation given to the patient must be derived 
from solid knowledge, experience, and research in this area, especially 
regarding expected side effects, which will be discussed further below. 
The possibility of refraining from radiation should also be considered. 
Based on histological findings as reported in 2009, Stephenson et al. 
[39] concluded that the probability of dying from PC after RP and PSA 
relapse is low, perhaps as low as a few percent within a period of 15 
years following the surgery. According to results described by 
Freedland et al. and by Andersen et al. [40,41], the most important 
factor in assessment of the risk of death after RP for PC is the PSA-
doubling time (PSADT), although other tumor characteristics can also 
provide valuable information in a risk evaluation. Figure 6 presents 
PC-specific survival in relation to PSADT showing the differences 
between a short doubling time of 3 months and a longer such time of 
15 months, with a very clear advantage in the latter group.  
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Figure 6 From Freedland et al. 2005, JAMA; published with permission from the 
Editor. 
 
 
If the choice is to consider SRT, there are uncertainties in the decision-
making, for example, regarding whether the PSA-producing cells are 
actually located in the area that can or is intended to be treated. It is 
obvious that the cancer cells that are generating the PSA value may be 
located in the local lymph nodes or, in the worst case, in distant 
metastases. However, as far as possible, this must be ruled out, because 
SRT will not cure a systematic, metastatic disease. According to some 
investigators [42-44], the most probable location of a local relapse 
after RP is in the vicinity of the anastomosis or in a retrovesical 
position. The surgical resection margins in each case must also be 
carefully considered. Still, there is currently no reliable way to 
visualize PSA-producing cells in patients with PSA values as low as 
0.2–0.5 ng/ml. Therefore, various tools for probability judgement have 
been developed in relation to findings in the surgical specimen, which, 
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together with PSA kinetics, can support and guide the decision 
making. There are some “prediction tools” that rely on these findings 
and can deliver a prognosis for the SRT. An example of this is from 
Memorial Sloan Kettering Cancer Center, NewYork, NY, USA which 
makes use of  PSA kinetics and pathological findings from the surgery 
for the individual and then presenting a prognosis on what to expect if 
the SRT is delivered. It is elaborated as an online tool so that the 
patients themselves can insert their own data. However, there is no 
prediction tool on what to expect if refraining the treatment which also 
could be a choice. 
 
 
 
 
Imaging to support decisions  
New diagnostic techniques based on visualization of PSA-producing 
cells are evolving, and the method Prostate-Specific antigen Membrane 
Antigen-Positron Emission Tomography, PSMA-PET, is appropriate. 
This approach uses the membrane antigen PSMA-11 marked with the 
radioactive isotope gallium-68, which has a half-life of 68 minutes and 
is therefore convenient for this imaging. The emission of positrons 
makes it possible to create three-dimensional PET scans that are 
further transformed in CT images and subsequently visualize the PSA-
producing cells/areas. The reliability of this diagnostic procedure in 
patients with increasing PSA after prostatectomy depends on the level 
of the PSA. Hoffmann et al. [45] retrospectively analyzed 581 patients 
by use of PSMA-PET scans performed upon PSA relapse after RP and 
RT, and the results showed that, for RP, the optimal cut-off value for 
PSA was 1.24 ng/ml for predicting positive and negative scans. As 
mentioned above, the optimal PSA value for SRT is low, 0.2 [37,38] 
and, at that level, the PSMA-PET technique in its current form is not 
really applicable. Still, it is possible that the results of a PSMA-PET 
can help prevent inaccurate treatment of patients diagnosed with 
metastases, which is also highly important in the clinical perspective. 
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TARGET IN SALVAGE RADIOTHERAPY 
The target                                                                                             
When RP is performed on a patient with PC, the whole prostate gland 
and the seminal vesicles are surgically removed. A new connection is 
created between the bladder neck and the external sphincter with the 
adjacent urethra, and this is achieved through downward displacement 
of the bladder (see Figure 7). Accordingly, the inferior (caudal) part of 
the bladder takes up the position formerly occupied by the prostate. 
The volume where the prostate had been located represents the target 
region [46], and the inferior part of the bladder is therefore 
unequivocally the midpoint of the radiation treatment. The bladder is 
an organ that constantly changes in size and, to some extent, also in 
location. The change in location is caused by increase in the bladder 
volume, and therefore substantial effort is made to standardize the 
volume during RT, which is discussed further below. 
 
Figure 7. Sequence of images representing pre- and post-surgery in prostate cancer, 
and the target outlined in green (from http://studynursing.blogspot.com/). 
 
 
 
Bladder 
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Contouring guidelines 
Contouring guidelines on how to define the postoperative PC treatment 
region (CTV/PTV) appeared at the beginning of this century and arose 
from international radiation associations such as the EORTC, the 
Radiation Therapy Oncology Group (RTOG), the Princess 
margaretHospital (PMH), and the Faculty of Radiation Oncology 
Genito-Urinary Group (FROGG) [47-50]. Development of these 
recommendations has been based on pragmatic discussions between   
urologists, radiation oncologists, and radiologists, which has resulted 
in guidelines that, to some extent differ from each other with varying 
definition of the CTV. As shown in Figure 8 Malone et al. [51] have 
illustrated the effect of disparities in treatment volume when defining 
the CTV in the same patient but according to different guidelines. 
 
 
   
Figure 8. CTV/PTV determined by four different guidelines: RTOG, EORTC, PMH, 
FROGG. 
Malone et al., 2012, Int J of Radiat Oncol Biol Phys; with permission from the 
Editor. 
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Thus, it can be concluded that there are disparities in the outlining          
of the CTV, and, in my opinion, this is one of the most uncertain 
factors when evaluating published studies. The occurrence of side 
effects should differ in relation to the extent of the CTV/PTV, and, 
reasonably, this will be seen as fewer side effects with a smaller 
irradiated volume. Unfortunately, reports in the literature seldom 
describe in what volume or according to what guideline the radiation 
energy has been delivered, which makes it more difficult to evaluate 
and compare the reported results of side effects. Not surprisingly, 
according to Cloak et al. [52], there are also differences between 
clinical colleagues regarding the extent of the target volume, even 
though the standard approach is to follow a specific guideline. 
 
 
 
PREPARING FOR RADIOTHERAPY 
 
Preparing the bladder and rectum 
The above-mentioned contouring guidelines differ in bladder 
recommendations, to be kept full, partly full, comfortably full but all 
prescribe that it is desirable to achieve a reproducible bladder volume 
during the following treatment sessions. The bladder volume can be 
controlled by the use of bladder protocols [53] in which the patients 
are recommended particular modes of fluid intake and voiding. There 
are a number of such protocols [54] that describe different ways to 
handle the outcome, and they underline that it is important to control 
the results (i.e., ensure a constant bladder filling). Some protocols call 
for daily measurement of bladder volume by ultrasound examination, a 
time-consuming task with implications that the patient is either to 
empty the bladder to some extent or increase the intake of fluids [55] 
and continue controls.  
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Similarly, there are differences in the recommendations for preparing 
the rectum for RT. Daily emptying of the rectum, following a gut diet 
or even by use of a rectal rod or balloon during treatment are strategies 
that are known to provide control over the position and volume of the 
rectum [56,57]. An invasive procedure designated “SpaceOAR” has 
been shown to significantly reduce late toxicity of the rectum [58], but, 
thus far, this procedure is applied only in primary RT for PC and is not 
yet approved for PRT. In SpaceOAR, a hydrogel substance that acts as 
a spacer is injected into the region between the prostate and rectum 
that dissolves within 6 months. To accomplish control and 
reproducibility of the size and location of the rectum is an important 
but troublesome task. Bell et al. [48] have studied this topic and found 
that, if the rectum changes volume and location, it will result in a 
geographic miss in the upper part of the target that will have an impact 
on the distribution of the radiation energy [59,60]. This suggests that 
dislocation of the rectum can interfere with the dose distribution and 
thus have a negative effect on both the target and the OaRs. The 
optimal way to handle the influence of the rectum in the target area, 
during treatment, may be a standardized matching procedure with 
CBCT, as proposed by Ost et al. [31]. 
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REGISTRATION AND EVALUATION OF 
SIDE EFFECTS 
 
The registration of side effects can be achieved by use of different      
schedules in which health care staff judge the way a patient perceives 
his own symptoms, and the observations made are recorded according 
to pre-described values. One such approach is the Common Toxicity 
Criteria scale elaborated by the European Organization for Research 
and Treatment of Cancer (EORTC), which gives an objective view of 
radiation-related toxicity [61]. To register, descriptions of the 
subjective symptoms obtained directly from the patient, the use of 
patient-reported outcome measure (PROM) questionnaires can be 
recommended, because they clearly reveal the patient’s own 
experience of troubles/symptoms and quality of life (QoL). One 
internationally frequently used PROM is the International Prostate 
Symptom Score (IPSS) which is used to evaluate urinary voiding 
symptoms, where the patient himself enters a chosen digit 
corresponding to his symptoms. Unfortunately, the PROM 
questionnaires are underutilized in published papers and studies, and 
there seem to be discrepancies between the ways that these instruments 
report side effects [62]. One example was presented by Sonn et al. 
[63], who found that there was physician patient disagreement in that 
the physician noted impairment in urinary and sexual function more 
often than pain and fatigue. 
 
Further, the EORTC has developed the PROM QoL questionnaire 
QLQ-C30 (Core Quality of Life Questionnaire) for general application 
in cancer patients and in cancer trials. Questionnaires specific for PC 
patients also exist, for example, the EPIC 26 (Expanded Prostate 
Cancer Index Composite) [64] and the SWOG QoL (Southwest 
Oncology group  Quality of Life) [65]. The QUFW94 (Questionnaire 
Umeå Fransson Widmark) is another questionnaire that is used in 
particular to study the side effects of RT in PC patients, and has been 
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developed to the “Prostate Cancer Symptom Scale” self-assessment 
questionnaire [66,67] that is frequently administered in Sweden via the 
NPCR (see Figure 9).  
 
 
NPCR and Prostate Cancer data Base Sweden, PCBaSe 
The NPCR was initiated to a limited extent in 1987 but includes all 
regions in Sweden since 1996, and the primary aim of this register is to 
present quality assurance work that is centrally administered and 
includes further reference back to the regional working groups. The 
NPCR database contains reports on diagnostic parameters, planned and 
executed primary treatment, treatment outcomes, and side effects. 
Since 2016, an interactive bulletin entitled “Ratten” is available online, 
which delivers updated reports from the NPCR on a daily basis [68]. 
A register-based resource for PC research known as PCBaSe was 
constructed in 2008 with the NPCR database as a hub. Development of 
that database has been achieved by use of the unique Swedish personal 
identity number, and various nationwide registers are linked to the 
NPCR, such as the following: the Cause of Death Register, the 
Swedish Cancer Register, the Prescribed Drug Register, and the 
National Patient Register. Thus, the NPCR serves as an important 
register-based resource and platform for PC research that is 
continuously up-dated and validated [69,70]. 
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Figure 9. Cover sheet of the “Prostate Cancer Symptom Scale” self-assessment 
questionnaire. With permission from the Steering group in NPCR 
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SIDE EFFECTS AND DOSE-VOLUME 
CONSIDERATIONS 
 
As mentioned above (see Figure 5), after RT delivered to any part of 
the body, it is necessary to take into account the balance between 
destruction of cancer cells and possible damage to remaining normal 
cells in the organs concerned. In PRT, the lower part of the bladder 
receives the total prescribed radiation dose and is most likely to suffer 
from side effects [71]. How pronounced these effects are is very 
individual, and the knowledge on this subject is poor, because data and 
reports often concern primary prostate RT in which a higher radiation 
dose is prescribed, and the urinary bladder is not in the center of the 
delivered radiation. Further, a method for reducing the risk of radiation 
to the bladder and rectum in primary prostate RT is the previously 
mentioned practice of IGRT with gold markers [72]. 
The rectum and the structures involved in sexual functioning are other 
areas that are to be affected by the radiation energy, the rectal wall, and 
for erectile structures also the preceding surgical procedure. The side 
effects currently observed after RT include symptoms in the urinary 
and gastrointestinal tracts and regarding sexual functioning, and in the 
short perspective also fatigue. 
There is a distinction between early (acute) and late side effects, or 
toxicity, with the symptoms considered to be early occurring within the 
first 6 months after RT and those deemed late appearing during the 
time thereafter. Almost all published evaluations have indicated that 
late side effects after PRT are usually mild [22,73]. Also, an 
assessment considering a possible correlation between acute and late 
toxicity has suggested that acute toxicity is an independent predictor of 
late rectal toxicity [74].  
Late toxicity is the topic further discussed below. 
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The urinary tract 
The side effects observed most often after PRT are increased 
frequency and urge, and also dysuria, whereas leakage (incontinence) 
is more seldom reported. This is noted in most studies performing 
PROM surveys [75-77], which also describe the side effects as being 
well tolerated. Radiation scoring schemas outlined by the 
RTOG/EORTC are focused on grading and have indicated that urinary 
toxicity of grade 2, 3 is rare in most studies (see the scoring schema for 
grading presented in Figure 10). Nonetheless, it seems that side effects 
from the urinary tract increases over time. Cozzarini et al. [78] found 
that the 8-year risk of grade 2 or 3 side effects was nearly 24% and 
primarily represented hematuria and incontinence, with a median 
interval to onset of 20 months. Other investigators have reported 
similar findings, including the increase in symptoms over time [73,79]. 
The dose-volume relationship with proposed constraint levels is more 
uncertain, because the bladder is an organ that constantly changes in 
volume, which also results in different positions of the bladder both 
during and between treatment sessions. Consequently, the treatment 
plan with a dose distribution based on the pCT can most likely not 
illustrate the true dose distribution pattern during the course of the 
whole treatment period. 
Considering the obvious difficulties in controlling the bladder volume, 
it has been suggested that some parts of the bladder are more sensitive 
to developing the side effects of radiation and therefore might be used 
as predictor sites. Cheung et al. [79] recently studied what  they called 
a “hot-spot” model relating grade > 1 toxicity of the dose to the hottest 
2.9% of the (full) bladder. Ghadjar et al. [80] further investigated the 
hot-spot theory in primary RT and found a significant association 
between high-dose spots in the trigone and relevant changes in IPSS. 
Hathcort et al. [81] proposed that the dose to the bladder neck in 
brachytherapy can be regarded as a strong predictor of developing 
acute and late toxicity. 
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In an organ-specific paper from the Quantitative Analyses of Normal 
Tissue Effects in the Clinic (QUANTEC) group, Viswanathan et al. 
[71] stated that there is no convincing proof that a dose-response 
relationship actually exists, and they also proposed that the symptoms 
in the urinary tract may arise from the urethra or from a prostate gland 
that has not been removed. Clearly, further investigations are needed to 
address this issue. 
 
 
 
Figure 10. The RTOG/EORTC scoring schema for late side effects in the bladder and 
small/large intestine (adapted from Ohri et al., 2012, Canadian Journal of Urology). 
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The gastrointestinal tract                                                  
Rectal inconveniences, toxicity, consists of especially bleeding, 
discharge of mucus and leakage of stools; though defecation urgency 
was the most prevalent in a PROM survey by Alsadius et al 2014, 
when investigating patients receiving different kinds of RT in prostate 
cancer[82,83]. Rectal bleeding has been described, according to RTOG 
grade 2, in a QUANTEC overview, occurring in about 5-20% in 
prostate cancer primary radiation series[83]. Such bleeding has been 
regarded as usually being self-limited, but in some patients it requires 
medication (e.g., suppositories), blood transfusion, or, in the worst 
case, surgical intervention such as a diversion (ostomy) [84]. 
 The correlation between DVH parameters and development of rectal 
bleeding has been described in earlier studies, and the following dose-
response constraint has been proposed [85,86]: > 60 Gy delivered to 
>35% of the rectal volume (representing about 90% if the prescribed 
dose is 70Gy in 2 Gy fractions) is significantly associated with late 
rectal toxicity. There are uncertainties in this context; Bruner et al. [87] 
compared the two techniques 3-DCRT and IMRT in primary PC 
treatment and found that  despite of reduced treatment volumes and 
doses to the OaRs in the IMRT technique, the PROM questionnaire 
could not reveal any differences in the symptoms reported by the 
patients. Most analyses of dose-volume parameters have been 
performed on patients receiving RT in a primary setting, and it is not 
clear whether these findings also apply to the postoperative group. 
Hence, there are differences in the prescribed dose, with approximately 
80 Gy delivered in 2 Gy fractions, given in the primary treatment and 
also in  IGRT with gold markers, compared to IGRT in PRT with 
matching to skeletal structures, which has a negative impact in the 
PRT group. It has also been proposed that earlier abdominal surgery, 
as done after prostatectomy, makes the patient less tolerant to radiation 
[88]. 
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Severe side effects, needing intervention 
Adverse events and surgical interventions associated with late side 
effects of PRT have been studied to a somewhat lesser extent. 
Showalter et al. [89] conducted a large retrospective cohort 
investigation of long-term adverse events in nearly 10,000 men with 
PC. These authors used primary care and hospital database registers 
and focused specifically on adverse events in the following areas after 
treatment for PC: gastrointestinal and genitourinary problems, erectile 
dysfunction, and hip fractures. They compared RP and RP+RT over a 
5-year follow-up period and found that the added exposure to RT after 
prostatectomy led to increased rates of gastrointestinal and non-
incontinence urinary events but not urinary incontinence events or 
erectile dysfunction. In a 5-year follow-up cohort study including a 
total of 37,000 men, Wallis et al. [90] compared three groups of PC 
patients treated with RP, RT, and RP+RT, respectively, according to 
their need for in-patient care, interventions, or procedures in the 
urinary or rectal tract. The complication rate was highest in the RT-
only group followed by the RP+RT group, and lowest in the RP-only 
group. However, it should be mentioned that that study had no 
information regarding possible use of ADT, which is often prescribed 
together with RT and can lead to a poorer result with respect to side 
effects. 
 
 
Erectile dysfunction 
The impact on erectile function when adding RT to a prostatectomized 
patient in the postoperative setting is difficult to evaluate, especially if 
there are no baseline data from before the RT. It has been proposed 
that the dose to the penile bulb can predict risk of erectile dysfunction, 
in primary RT, with a constraint level of 20 Gy [91]. Still, it is highly 
likely, in PRT, that the surgery itself additionally influences the 
erectile function. Reports on erectile dysfunction after PRT often show 
very little deterioration, if any at all [65,92]. 
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Secondary malignancies                                                          
Development of secondary malignancies after RT for PC is particularly 
important to consider when handling younger patients. The aspects of 
dose response and time lag period, as well as age, seem to play a 
crucial role in the occurrence of secondary malignancy. Reports 
concerning primary radiation for PC predominantly deal with an 
increased risk of subsequent bladder and colorectal cancer [93], 
although lung cancer is also indicated. Brenner et al. [94] observed 
only a limited rise in the risk of secondary malignancies in the form of 
solid tumors, but this risk increased in long-term (> 10-year) survivors 
in primary radiated patients compared to operated men. Zelefsky et al. 
[95] compared primary RT (both EBRT and brachytherapy) with RP 
but, during a 10-year follow-up, found no significant difference 
between the two groups after adjusting for age and smoking habits.         
A number of different treatment strategies (e.g.,  3-DCRT, IMRT, 
VMAT, and protons) have been investigated with proposal on varying 
risks linked to the different methods [96,97]. Still, in a systematic 
review and meta-analysis, Wallis et al. [98] found that the absolute 
rates of secondary malignancies after RT for PC were low. 
There are fewer reports on secondary malignancy in SRT. 
Aksnessæther et al. [99] conducted a register-based study in Norway to 
compare RP and different RTs, including PRT, with regard to 
secondary malignancies, and the results showed that only the risk of 
bladder cancer was increased in the PRT group compared to the RP 
group. In one of the previously mentioned investigations performed by 
Wallis et al. [90], both primary RT and PRT were compared with RP 
regarding the risk of secondary malignancy of any kind, and the 
increase in risk was found to be highest in the RT-only group followed 
by the PRT group, and lowest in the RP group. It is evident that further 
studies are needed to explore the impact of PRT on the risk of 
developing secondary malignancies, and such assessments should take 
the following parameters into account: treatment modality, radiation 
dose, patient age, and other as yet unidentified confounders. 
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2 AIM 
The overall aim of the research leading to this thesis was to evaluate 
and improve the practical preparations for postoperative radiotherapy 
in prostate cancer and to assess the side effects in a long-term 
perspective.  
 
Ethical approval was granted for each of the four studies, which have 
the following objectives: 
 
PAPER I  
To investigate post-radiation morbidity in a long-term perspective as 
outlined in a PROM survey, comparing to a matched control group of 
men treated only with RP. 
 
PAPER II  
To evaluate dose-response parameters related to patient reported rectal 
bleeding and assess the risk related to two different radiation treatment 
techniques. 
 
PAPER III 
To evaluate the presence of late, side-effects with need of surgical 
interventions, in a large unselected cohort by comparing men treated 
with RP exposed to RT with a matched control group non-exposed to 
RT. We also investigated the development of secondary malignancies 
and cause of death. 
 
PAPER IV  
To evaluate the impact on bladder-filling of two different bladder 
filling protocols and to evaluate how different levels of bladder filling 
affect the localization and probable coverage of the target. 
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 3 Methods and methodological 
considerations 
 
Paper I 
All men who had undergone SRT after RP in the Western Region in 
Sweden during the period 2005-2010 were invited to participate in a 
mailed PROM survey. Men who had only undergone RP were selected 
from the NPCR database to serve as a matched control group, and 
those subjects were invited to complete the PROM survey in the same 
manner as the SRT group. The matching procedure was performed 
according to age, year of RP, and operating hospital. The SRT had 
been delivered as 2 Gy per fraction on 35 occasions to a total dose of 
70 Gy, mainly with a 3DCRT technique (photon beam energy 15 MV) 
with a few exceptions (3% with IMRT technique). 
We used the NPCR “Prostate Cancer Symptom Scale” self-assessment 
instrument, which is frequently administered within the field of PC in 
Sweden. Along with the survey document, a health declaration form 
(HDF) was attached that included questions on diseases, experienced 
symptoms, smoking habits, and pharmacological treatment. A 
reminder was sent if the survey was not returned within one month. 
The self-assessment survey consists of 53 questions divided into 
different symptom areas. We selected 14 questions that represented 
symptoms that would most likely refer to RT in PC and divided them 
into four different groups according to the area they affected: (1) the 
urinary tract, including incontinence and other urinary symptoms; (2) 
the rectal tract, as leakage of stools and discharge of blood; (3) sexual 
function; (4) general health and QoL.   
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In addition, information on severe side effects was obtained from 
medical records for men who were deceased or did not participate in 
the survey. 
 
Methodological considerations  
The goal of this study was to provide a better understanding of what 
side effects patients experience in a long-term perspective after SRT. A 
PROM survey and an HDF were administered to the SRT group, 
which included patients who were registered in our treatment database 
system as having undergone SRT during the investigated time period. 
Patients to create a control group were chosen from the NPCR patient 
database to match the SRT group with regard to age, year of surgery, 
and hospital. It is possible that matching according to tumor 
characteristics would have resulted in a better comparison between the 
groups, but that was not possible due to lack of access to the complete 
pathoanatomical diagnosis data in the control group. Also, during the 
matching of the two patient groups, we did not consider potential bias 
from any conceivable future events (related to RT), and this might be 
considered a weakness of our study. Also, the actual oncological result, 
recorded as PSA values, was not known during the related follow-up, 
information that might have been useful even though the aim of our 
study was not to present oncological findings. We discussed what 
PROM survey would be most suitable, and this led to our choice of the 
instrument used nationally in Sweden: the NPCR “Prostate Cancer 
Symptom Scale” self-assessment. This instrument originated from the 
QUFW94 questionnaire, which was designed in 1994 and was further 
validated in 2001 and 2010. One reason for choosing the NPCR 
assessment was that it is widely used in Sweden for thousands of PC 
patients, and it has a system for handling the responses electronically. 
This survey has also been used in previously published studies. The 
HDF, which is applied on a daily basis at our department, could not be 
assessed automatically, and this led to considerable amounts of extra 
work such as the necessity of interpreting nearly illegible handwriting 
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In addition, information on severe side effects was obtained from 
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and entering information in the database, tasks that entail, the risk of 
making mistakes related to the “human factor”. Another challenge was 
having to search through medical records to find diagnoses and 
medical history of deceased and missing patients in order to avoid 
drawing misleading conclusions on possible side-effects. 
Before actually applying the NPCR survey, we addressed the issue of 
how we would analyze the patients’ responses by including questions 
that would not influence the answers that were given in a special 
direction. The response alternatives were dichotomized between “not 
at all” (1) and answers indicating any problem related to the specific 
question (2–4), although this differed for the items concerning leakage 
and QoL (see Appendix in Paper I). The collected data were analyzed 
by use of Poisson regression which gives relative risk estimates with 
corresponding confidence intervals (CIs). It seemed more appropriate 
to present the results as relative risks than as odds ratios of logistic 
regression, since we believe that relative risk is easier to assess. 
Inasmuch as a major part of the results concerned patient-reported 
rectal bleeding, it is also appropriate to mention the related question in 
the survey (i.e., no. 28): “Do you have blood in your stools?” The 
response alternatives were “no”, “a little”, “to some extent”, and “very 
much”. This grading of the response can be compared with and 
commented on in relation to other PROM questionnaires, which 
provide more detailed descriptions of the quantity and duration of the 
bleeding. Still, the wording of the response to this item in our 
questionnaire makes it possible to differentiate between “no bleeding” 
and “any bleeding”, which has served as the distinguishing feature in 
our model of evaluation: no bleeding = 0, and any bleeding = 1. 
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Paper II 
Group 1 in this study consisted of the same SRT patients as included in 
the SRT group in our PROM survey (Paper I, see above), and these 
subjects were further analyzed for how the risk of rectal bleeding is 
affected by the rectal dose distribution. This investigation also 
included a second SRT group treated with VMAT at our department, 
here designated Group 2, which was retrospectively chosen to enable 
comparison with rectal DVH parameters in Group 1. Fifty-six (22%) of 
the patients in Group 1 had reported rectal bleeding to any extent in the 
PROM survey described in Paper I, which represented the main result 
of that survey. 
Group 1 consisted of patients treated with 3DCRT in 2005–2010 at our 
hospital, and Group 2 was selected to include all patients treated with 
the VMAT technique in 2017–2018, at that time fully implemented in 
the department. In both groups, treatment and preparations for 
treatment were performed according to the standard protocols at the 
department, which did not include any specific rectal arrangement 
except instructions to empty the rectum prior to undergoing the 
planning CT. Target delineation varied over the study periods, with 
changes from a smaller toward a larger CTV according to existing 
guidelines (i.e., from EORTC to RTOG recommendations). Over time, 
CTV to PTV margins were gradually being reduced from 15 mm to 10 
mm. However, the procedure for delineation of the rectum was 
identical in the two groups. With the treatment delivered as 2 Gy per 
fraction for 7 weeks to achieve a total dose of 70 Gy. A laser-based 
setup was followed by orthogonal kilovoltage or megavoltage 
positioning of bony anatomy with different time schedules: in Group 1, 
the average of the four first fractions was the base for setup, completed 
with weekly controls; in Group 2, daily orthogonal imaging was 
conducted. Using the self-reported data on rectal bleeding in Group 1, 
a  dose-response analysis was performed to quantify the impact of 
rectal DVH parameters on the risk of rectal bleeding. The relative 
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rectal volume receiving at least 35Gy and 63Gy were separately 
investigated in univariable logistic regression using the maximum 
likelihood estimation method. The resulting dose response 
relationships between rectal V35Gy and V63Gy, called dose-response 
curves, were used to calculate the probability of rectal bleeding for 
each patient in both groups with purpose to investigate the potential 
benefits of treating patients with VMAT instead of 3DCRT. 
Methodological considerations  
The dose-response relationships considered in this study were those 
between the dose distribution in the rectum and reported rectal 
bleeding, and the data were extracted from the Eclipse treatment 
planning system where treatment-related data of interest are available. 
Rectal DVH parameters from both groups were included in the 
analysis. In Group 1, we had identified 56 of 255 men that reported 
rectal bleeding of any grade as compared to no rectal bleeding. In line 
with the above-mentioned goal, we performed a dose-response analysis 
to quantify the impact of rectal DVH parameters in the 3DCRT-treated 
Group 1. This relationship was then used to estimate the risk of rectal 
bleeding using the two rectal volume objectives applied at our 
department, V35Gy (50% of prescribed total dose) and V63Gy (90% of     
prescribed total dose). This resulted in two dose-response curves, 
which were then used to calculate the risk of rectal bleeding for each 
patient in both groups. Here we used PROM data including patients 
reports of any rectal bleeding, and we undertook risk assessment 
calculations that could subsequently be used in future development of 
evidence-based rectal dose constraint levels. 
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Paper III 
All patients in Sweden that had been treated with RP in 1997–2016 
were selected from the NPCR and investigated to choose a large cohort 
of men to be investigated according to: men who underwent RP and 
received RT postoperatively, called the  exposed group; and men who 
underwent RP but had no postoperative RT, referred to as the          
non-exposed group. As the database for this study, we used the 
PCBaSe, which consists of the NPCR and its linkage to more than 
eight different national patient registers in Sweden, such as the 
following: the National Patient Registry, the Prescribed Drug Register, 
the Cancer Registry, and the Cause of Death Register. 
After exclusions, a matching procedure was performed. The matching 
procedure was developed to avoid possible bias, in order to not be 
based on future information when considering date of RT as time zero. 
Prior to conducting this matching, censoring was performed if other 
malignancies, metastases, and symptoms and/or surgical procedures in 
the urinary or rectal tract had occurred before RT. Matching in the 
groups was done according to year of birth, year of surgery, and 
Charlson comorbidity index (CCI). A non-radiated man was given a 
fictive RT date that corresponded to the true RT date of a matched 
radiated man (see the matching algorithm in Appendix in Paper III). 
Differences between the two groups were investigated with regard to 
these outcome measures: surgical procedures in the urinary or rectal 
tract; development of secondary malignancies; mortality, considering 
deaths due to PC and all other causes. Kaplan-Meier survival analysis 
was performed on each outcome, and, to avoid overestimating the 
incidence associated with competing risk, incidence curves based on 
competing risk were constructed. Rate ratios between the two groups 
were calculated by Poisson regression analysis, and CIs were 
constructed based on profile likelihood. 
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Methodological considerations  
The analysis of severe side effects after PRT reported in Paper III was 
based on data from different national registers linked to the NPCR, 
which make up the PCBaSe. The capture rate of the PCBaSe is known 
to be very good, described as 98% in the NPCR, and reporting is 
actually mandatory by law for some of these records, such as the 
Swedish Cancer Registry. The data on performed radiation therapies 
were updated with reliable information from 17 of 18 existing 
radiotherapy units in Sweden (compiled by RetroRad, 1998–2007), 
and this was necessary because the reporting of radiation data to the 
NPCR had not been initiated until 2008. Using the PCBaSe in our 
investigation was an obvious choice due to the reliability of this 
database and the large number of research papers that have emanated 
from it. 
 
The data used as a basis for this study represented all men with PC 
who underwent RP in 1997–2016 in Sweden. From this cohort, all 
those who had also received RT as postoperative treatment were 
selected and designated as the exposed (RP+RT) group. Several of the 
patients were excluded before the matching procedure was performed. 
In short, subjects were excluded due to living in a region with missing       
PRT data, being lost to follow-up, and, most extensively, due to lack of 
information on timing of ADT. The matching strategy was developed 
to avoid “immortal time bias”. In other words, the information on the 
groups we wanted to compare could not be based on unknown future 
information, which might have precluded the possibility of achieving 
comparable groups. 
The matching procedure was time consuming and had to be redone          
more than once. For instance, data on surgical procedures and ICD-10 
diagnoses became limited to us since Socialstyrelsen, SoS (in English: 
the National Board of Health and Welfare) implements restrictions on 
the availability of codes in the National Patient Registry in PCBaSe. 
This meant that we could not directly address our own selected codes 
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but had to relate to the prechosen codes given by SoS. Though, with 
the codes from SoS as first selection, other registered codes appeared, 
often the ones we had as a first choice and, as a whole, we considered 
that this did not, in any important way, influence the analysis. We 
investigated the cumulative incidence based on Kaplan-Meier 
estimation, and competing risk curves were constructed to ascertain 
whether censored events resulted in an overestimation of the 
cumulative incidence of the studied event. 
Rate ratios were calculated by Poisson regression analysis. An 
alternative could have been to apply Cox regression analysis, but we 
found the relative risk and rate ratio easier to interpret. Furthermore, 
the hazard ratio from Cox analysis is often considered to be similar to 
the rate ratio, as we also found to be the case in the analysis of our 
data. Absolute risk calculations appeared as an additional analysis to 
perform, not yet completed but highly interesting in the evaluation. 
The sectioning in ART or SRT is also an additional analysis to 
perform, yet with some difficulties in the division between groups, 
possibly through the time since surgery information, since the 
ordinated radiation dose not is conclusive. 
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Paper IV 
From the outpatient clinic, 32 patients with PSA relapse were invited 
and subsequently allocated to use of one of two different bladder 
filling protocols before a planned SRT treatment. This was done in a 
strictly time-dependent order, with every second patient assigned 
alternately to the two groups. 
The two protocols stipulated the following: 
Group 1 Voiding and drinking 300 ml of water 1 hour before the pCT 
and before each treatment occasion. 
Group 2 No instructions other than to keep a comfortably full bladder 
before the pCT and before each treatment occasion. 
 
The SRT was delivered as 2 Gy per fraction on 35 occasions to achieve 
a total of 70 Gy, thus requiring 7 weeks of treatment. A planning CT 
(pCT) followed by a CBCT performed weekly during the treatment 
period was registered to the pCT and further analyzed. Volumes of the 
bladder and CTV/PTV data were collected from the treatment planning 
system (Eclipse, Varian Medical Systems, Palo Alto, CA, USA), and 
the bladder volumes from the CBCTs were delineated and measured. 
The difference in bladder extension between the pCT and CBCT was 
measured both cranially and caudally (see Figure 11).        
 The variation in the volume of the bladder covered with 95% of the 
dose (V95%,bladder) in the treatment positions was estimated based on the 
DVH and correlated with the corresponding bladder volume. 
On a weekly basis, the patients were asked how well they had been 
able to follow the bladder protocol instructions, and the responses were 
registered by members of the clinical staff. 
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Figure 11. An example of pCT and CBCT images in a sagittal view matched and stored on top 
of each other. Colors indicate the following: bladder (green and orange), CTV (red), PTV 
(blue), Distance in the two-dimensional direction between different bladder volumes was 
measured cranially and caudally, arrow indicating positive (+) measurement.  
Methodological considerations 
In this study, our intention was to randomize patients to two separate 
groups with different bladder filling regimens, and a power calculation         
(assuming that the true mean difference between groups is 1.325 times 
the standard deviation, we had 80% power to detect this difference for 
a two-sided confidence level of 0.05 ) recommended that a total of 20 
patients be included, 10 assigned to each group. The randomization 
was organized in a simple manner by allocating each patient to either 
protocol in the order in which they came to the outpatient ward. Later, 
after the manuscript had already been submitted for publication, we 
recognized that the rules for randomization had not been fulfilled; that 
is, the random sample selection should have been organized in a 
different way, possibly via a database selection. 
 
The analysis was based on the planning CTs and CBCTs of each 
patient, the latter performed weekly. It was a challenge for the author 
to carry out all registrations between pCT and CBCTs and the 
delineations and measurements on the CT/CBCT images, but it was 
definitely an advantage that a single person was responsible for all 
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these tasks. There was no indication of which group each patient was 
associated with at the time of delineation. 
 
The practical handling of the studied patients in the treatment ward 
differed very little from the routine practice at the department. Still, 
although the patients were questioned regarding how well they were 
able to follow the instructions on fluid intake and voiding given in the 
bladder protocol, their responses were not always registered. This can 
be explained by the fact that the department is not a research unit, and 
the recording of the results reflects the ordinary daily work at that 
facility. 
 
Other potential approaches to achieve the same results for bladder 
volume measurements include ultrasound (US) measurements, as have 
been performed by other investigators. However, such measurements 
would have required introduction of a new and very user-dependent 
technique at the department, a strategy that was not realistic at that 
time. Furthermore, the US method would not have been appropriate for 
evaluating the effect of coverage of the target or made possible the 
measurements cranially and caudally. 
 
The choice of V95%bladder to evaluate the potential effect on increased 
irradiation of the bladder with increased bladder volume appeared as a 
possibility, and to relate to the finding of a stable localization of the 
distal part of the CTV. Though, conclusions could only be drawn when 
delineating the target according to EORTC which advocates smaller 
CTV.  
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Statistical methods used in the studies 
The statistical analyses were performed using R Statistical Software 
Matlab (version 2019b; The MathWorks Inc., Natick, MA, USA) and 
SPSS.  
Different statistical methods were applied in the four studies, because 
we analyzed different types of data on different topics. The statistical 
methods vary from quite basal, for example, considering medians and 
relative risks, to more advanced, such as analysis of survival and 
competing risk. 
 
Paper I 
In the analysis of the data from the PROM survey in the first study, we 
calculated the relative risks between the SRT and the reference group. 
To describe the margin of error, corresponding 95% CIs were 
calculated using Poisson regression with robust error variances. In the 
SRT group, the effects of age, PTV, and length of follow-up on the 
responses were investigated through dichotomization at median values. 
For each question in the survey, the proportion of missing answers was 
calculated based on available responses. 
 
Paper II 
In this study on rectal bleeding and dose-response relationships, we 
extracted radiation therapy data of interest from Eclipse using its 
capabilities for automatic data extraction. Dose-response data were 
investigated for patients in Group 1 (the PROM-reporting group), and 
they contributed with either 1 = any bleeding or 0 = no bleeding. The 
two dose-volume levels, V35Gy and V63Gy, were investigated separately 
in univariable logistic regression according to the maximum likelihood 
estimation method. The result is the s-shaped (logistic) curves that best 
described the risk of rectal bleeding as a function of either V35Gy or 
V63Gy. 
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Statistical significance for the models was assessed with the likelihood 
ratio test, and p-values of < 0.05 were considered statistically 
significant. Confidence intervals for the dose-response curves were 
estimated with bootstrapping, that is, random sampling with 
replacement using 5,000 bootstrap samples. 
 
The dose-response relationships curves were used to calculate the 
probability of rectal bleeding for each patient in both groups. Welch’s 
t-test was applied to assess differences between the two groups with 
regard to rectal V35Gy and V63 Gy, and the corresponding calculated 
probabilities. A linear regression model was used to evaluate the 
relationship between PTV and rectal doses V35Gy and V63Gy. 
 
 
Paper III 
The follow-up time, with a maximum of 15 years, started at the true        
or fictive RT date. The collected data on the following events were 
censored at first date of occurrence: emigration, date of death, start of 
ADT or surgical castration, and, for the non-exposed men, also for 
undergoing RT. However, data on ADT or surgical castration were not 
censored from the analysis of secondary malignancies and PC or all-
cause mortality. 
 
Kaplan-Meier estimation served as the basis for the assessment of 
cumulative incidence, and competing risk analysis curves were 
constructed to address the risk of overestimation of incidence of the 
evaluated event. Comparison of the curves showed only negligible or 
small differences and no appreciable effect on the relationship between 
the curves. Poisson regression analysis was applied to calculate risk 
ratios and rate ratios between the two groups and the associated 
confidence intervals, based on profile likelihood. 
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Paper IV                                                                                                    
In this study focused on variation in bladder filling, we calculated 
medians in bladder volume within individuals, within groups, and 
between groups to enable comparison of the observations. For this 
purpose, we used a linear mixed model that took into account the 
repeated measurements for each individual. To meet the assumption of 
normal distribution, the data were analyzed on a logarithmic scale. 
Pooled within-individual standard deviations were estimated. 
Spearman correlations were calculated to measure the degree of 
association between bladder volume and, respectively, the cranial and 
caudal distances noted at each visit. Thereafter, weighted medians of 
the Spearman correlations were chosen as the measure of overall 
correlation, and the number of patients per visit served as weights. CIs 
were estimated by bootstrapping, with 10,000 bootstraps for each 
group. 
A linear mixed model was used to investigate the increase in  95% 
dose to the bladder volume (V95%bladder) with increased total bladder 
volume. In this model, the result for each individual patient  had its 
own slope and intercept with means depending on group. The mean 
slopes of V95%,bladder versus bladder volume in the two groups were 
estimated and compared. 
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4 RESULTS 
Paper I 
 
In the SRT group 255 patients responded to the survey, 79% of invited 
and in reference group 485 responded ,74% of invited. 
ADT was prescribed for 22% in the SRT group and 6% in the 
reference group. The median time from surgery to survey was 10 years 
in both groups, and the median time after radiation to the survey was 
6.7 years. 
 
Comparison of the two groups 
The impact of SRT was most pronounced on rectal symptoms, with 
relative risk (=risk ratios=RR) of 1.7 to 6.5. The effect was more 
limited in the urinary symptom group, with RRs ranging from 1.2 to 
1.4. For general health, QoL, and sexual symptoms, all the RRs were 
< 1.1. Also, the response rate for the question on sexual activeness (Q 
38) was 30% in the SRT group and 32% in the reference group. 
Intensity of symptoms was investigated and plotted, which showed that 
having any rectal bleeding was reported by 22% in the SRT group 
compared to 3% in the reference group. Furthermore, fecal leakage of 
any extent was reported by 19% in the SRT group and 11% in the 
reference group, whereas intensity of other symptoms was generally 
low. 
 
When comparing the two groups, the use of ADT did not seem to 
influence the answers to the survey. The presence of severe symptoms 
indicated by a response of 4/5 (worst grade) for at least one of several 
selected questions (i.e., nos. 13, 15, 18, 24, 26, and 28) was noted for 
24% in the SRT group and 11% in the reference group. Dividing this 
into having at least one severe urinary symptom was reported by 16% 
in the SRT group and 9% in the reference group, and having at least 
one severe rectal symptom was reported by 8% and 2%, respectively. 
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SRT-only group 
With older age, the risk was higher for the reporting of urinary leakage 
and sexual activity. With increasing time after radiation, higher RRs 
were seen for rectal symptoms such as leakage and bother, whereas 
rectal bleeding became less frequent over time. Increasing time 
between surgery and radiation led to a low RR of close to 0.9, 
indicating a positive effect on QoL and incontinence. Also, the size of 
PTV had an impact on the self-assessed general health and QoL, both 
of which were reported as worse with a larger PTV. 
 
Non-responders and deceased 
In all, 236 men did not respond to the survey: 69 in the SRT group and 
167 in the reference group. Severe side effects such as bleeding 
requiring treatment and deviation surgery were found in four patients 
in the SRT group but none in the reference group. For the 46 deceased 
men in the SRT group, it was difficult to address the symptoms related 
to either the RT or malignancies other than PC. Four men had suffered 
urinary incontinence that required a surgical procedure (AMS 800), 
and one had fecal incontinence. Considering all 46 who died in the 
SRT group, death was due to PC in about half of the subjects, 
cardiovascular disease in four, and other malignancies in the remaining 
patients. 
 
More detailed results are presented in Paper I. 
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Paper II 
 
The analysis in this study covered data on 255 patients in Group 1 and 
253 in Group 2. In Group 1, the treatment was delivered as 3DCRT to 
nearly all patients, although seven (3%) were treated with IMRT. In 
Group 2, all patients were treated with a VMAT technique. 
 
When assessing the dose-response in rectal bleeding relative to V35Gy 
and V63Gy, significance was obtained for both parameters (p = 0.005 
and p = 0.003, respectively; see estimated dose-response relationships 
and 95% CIs in Figure 2 in Paper II). The observed prevalence of 
rectal bleeding was 22% in Group1, whereas the average calculated 
risk of rectal bleeding was about 14% in Group 2 according to our 
estimated dose-response relationship. Also, according to relative 
average rectal volume, the V35Gy was 17.9% larger (95% CI 15.6–19.7) 
in Group 1 than in Group 2, and V63Gy was 12.3% larger (95% CI 
11.0–13.5) in Group 1. 
 
Our calculated dose-response model also indicated that the average 
risk of rectal bleeding with V35Gy as parameter was 8% larger in Group 
1 than in Group 2, and with V63Gy as parameter it was 9.2% larger in 
Group 1. In Group 1 and Group 2, the values for average delineated 
rectal volume were 73.5 ± 26.6 and 72.6 ± 26.2 cm3, and the average 
PTV values were 177 ± 53 and 221 ± 67 cm3, respectively. Increasing 
PTV in Group 1 and Group 2 by 100 cm3 increased the rectal V35Gy by 
on average 4.8% and 3.1%, and the rectal V63Gy by 3.1% and 1.2%, 
respectively. 
 
More detailed results are presented in Paper II. 
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Paper III 
According to the NPCR and PCBaSe, 40,962 men were treated with 
RP in Sweden from 1 January 1997 to 31 December 2016. After 
exclusions, 37,848 men with RP were available for matching: 4,902 of 
those men had also had RT and hence were designated as exposed, and 
32,946 did not have RT and were thus denoted non-exposed. The 
matching procedure resulted in a study cohort with 3494 exposed men 
and 6988 matched.  
Median age at RT or fictive RT was 65 years (IQR 61–69 years), and 
the radiation dose was ≤ 66 Gy for 610 men (17.5%) and > 66 Gy for 
2,884 men (82.5%). Median follow-up time after RT or fictive RT was 
4.4 years (IQR 1.7–7.9 years) in the exposed group and 5.1 years (IQR 
2.0–8.7 years) in the non-exposed group. 
 
Differences between the exposed and the non-exposed group are 
presented as rate ratios (RR). Compared to the non-exposed group, in 
the exposed group the risk of any surgical intervention in the urinary 
tract was 3.66 times higher (95% CI 2.85–4.72), the risk of urinary 
diversion with or without cystectomy was 4.41 times higher (95% CI 
2.25, 9.12), and the risk of endoscopic procedures in the urinary tract 
was 5.88 times higher (95% CI 4.15, 8.47). In addition, the risk of 
interventions of any kind in the rectal tract was 1.16 times higher (95% 
CI 0.86–1.57) in the exposed group, although this difference was not 
statistically significant. 
 
Also, the risk of bladder cancer was 2.30 times higher (95% CI 
1.54–3.45) and the risk of rectal cancer was about the same for the 
exposed subjects compared to non-exposed. Considering the men 
who had undergone cystectomy, three out of 20 (15%) in the 
exposed group had a diagnosis of bladder cancer before the 
intervention, and the corresponding number in the non-exposed 
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group was five out of seven (71%). For colostomy and/or rectal 
resection (amputation), four men out of 22 (18%) in the exposed 
group had a diagnosis of colorectal cancer before the surgical 
intervention, compared to 10 out of 34 (29%) in the non-exposed 
group. 
Compared to the non-exposed group, in the exposed group the 
prostate cancer mortality was higher (RR 5.79, 95% CI 4.24–8.04), 
the non-prostate cancer mortality was about the same (RR 0.98, 
95% CI 0.83–1.15), and the all-cause mortality was 1.5 times 
higher (RR 1.48 95% CI 1.30–1.70). According to age (at start of 
RT or fictive RT), non-prostate-associated mortality was not 
increased in men aged < 70 years (RR 1.04, 95% CI 0.85–1.26) or 
in men aged ≥ 70 years (RR 0.86, 95% CI 0.64–1.15) in the 
exposed group compared to the non-exposed group. 
More detailed results are presented in Paper III. 
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Paper IV 
The results of this study were based on 29 patients, 13 assigned to 
Group 1 and 16 to Group 2. Ninety-five CBCTs were performed in 
Group 1 and 119 in Group 2. Measured bladder volumes (median) per 
individual were 68–264 ml in Group 1 and 54–287 ml in Group 2, and 
medians per group were 120 ml (95% CI 93–154) in Group 1 and 123 
ml (95% CI 98–155) in Group 2. The intraindividual variation in 
bladder volume presented as standard deviation was 64 ml in Group 1 
and 61 ml in Group 2, suggesting a high level of intra-individual 
variation in both groups, with no clear difference between the groups. 
With increasing volume, the bladder extended cranially; the larger the 
bladder volume, the greater was the extension, with correlations of 
0.82 (95% CI 0.52–0.98) in Group 1 and 0.90 (95% CI 0.84–0.96) in 
Group 2. There was very little variation in caudal distance within each 
individual, and there was essentially no correlation with bladder 
volume 0.08 [95% CI 0.55–0.31] in Group 1 and 0.12  [95% CI 0.43–
(-)0.33) in Group 2; see Figure 12 below.  
The results for V95%bladder were similar in the two groups: medians per 
patient ranged from 13 to 39 ml in Group 1 and from 11 to 41 ml in 
Group 2. The difference between the groups regarding 100-ml increase 
in bladder volume was 0.2 ml (95% CI –0.11, 0.16). 
Compliance with bladder filling instructions could be evaluated in 25 
of the 29 patients (12 in Group 1 and 13 in Group 2). In Group 1, 5/12 
patients (42%) had been able to prepare themselves according to the 
instructions on about 50% of the RT occasions. In Group 2, with free 
fluid intake and voiding, the mode of preparation varied, and, 
surprisingly, four patients (31%) had prepared for treatment in a 
manner similar to that applied in Group 1. 
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Figure 12. Correlation of bladder volume to measured distance on different 
treatment occasions in both groups. Cranial distance is shown to the left and caudal 
distance to the right. 
More detailed results are presented in Paper IV. 
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5 GENERAL DISCUSSION  
The present research has been in progress for almost 10 years, and 
during this time there have been many new findings, observations, and 
technical developments in the field of radiation that have influenced 
the concept of PRT after RP in PC patients. The results of a meta-
analysis [26] presented at the meeting of the European Society for 
Medical Oncology (ESMO) held in September 2019 revealed that SRT 
can be preferable to ART, which is an awaited conclusion, because this 
can facilitate the difficult decision of when to propose the PRT. So 
now it is appropriate to focus on SRT and not ART. The diagnostic 
procedure PSMA-PET has been introduced, which offers the 
possibility to detect relapse of PC, but unfortunately it is not yet 
applicable at the low PSA value that supports the decision to perform 
PRT [45]. Using MRT images as support in establishing a target 
definition is now standard at our department and elsewhere. Other 
improvements in the field of RT that have been made during the last 10 
years include the launching of advanced treatment methods such as 
VMAT and the continuing progress in finding better IGRT methods in 
the RT field. The studies assessing a hypo fractionated treatment 
regimen to reduce the number of fractions has provided results, and the 
research in this area continues [100]. Increasing utilization of PROM 
surveys, even as an online e-PROM, is now a reality for all patients in 
Sweden receiving curative treatment for PC, and this includes 
continued evaluation scheduled over time. 
 
Thus, the above-mentioned aim of optimizing PRT is being addressed 
continuously, particularly with respect to evaluating the side effects. 
The findings of our PROM study (Paper I) revealed that, compared to 
the reference (RP only) group, the SRT group reported more side 
effects in the rectal tract and to some extent also in the urinary tract, 
whereas no differences were found between the two groups with 
regard to sexual function or global QoL. Rectal bleeding was the most 
obvious finding, reported as “any extent” by 22% of the men in the 
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Figure 12. Correlation of bladder volume to measured distance on different 
treatment occasions in both groups. Cranial distance is shown to the left and caudal 
distance to the right. 
More detailed results are presented in Paper IV. 
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SRT group but only 3% in the reference group; leakage of stools was 
reported by 19% in the SRT group and 11% in the reference group. 
Hence, some of the studied patients did have a problem with stool 
leakage, but the differences in reporting between the two groups were 
not as pronounced for this side effect as for rectal bleeding. Similar 
observations have also been described by other investigators. Alsadius 
et al. [82] used a PROM questionnaire to study a cohort comprising all 
categories of PC patients given RT and found that the most frequently 
reported symptoms from the rectal tract were leakage and defecation 
urgency. The assessment of side effects can be achieved with self-
reported surveys, such as a PROM, or by clinical staff estimating the 
rates of symptoms in assessment scales [62,101]. We used a PROM 
questionnaire [66], which we believe illustrates symptoms in a 
clinically more relevant way compared to, for example, the objective 
RTOG/EORTC assessment scales [61]. The most relevant strategy for 
judging the symptoms is probably a combination of the two methods. 
Furthermore, it is necessary to bear in mind the possibility of other 
rectal disorders that can cause the bleeding [84] and undertake relevant 
examinations when such symptoms occur after RT. 
Side effects can appear many years after RT, and therefore long-term 
follow-up is required [102]. The follow-up time in studies is 
commonly limited to a few years, often a median of up to 5 years, 
although with some exceptions [23,24]. The median follow-up time in 
our PROM study was 6.7 years after SRT and 10 years after RP, which 
are periods of reasonable length. The main observation in Paper I was 
an approximately six times higher level of rectal bleeding in the SRT 
group, although we also noted that the rectal bleeding diminished over 
time, which has been reported by other authors as well [103,104]. 
Nevertheless, Berlin et al. [105] found that the side effects of RT 
remained stable for at least 5 years. 
In Paper I, urinary symptoms were frequently reported by both the 
SRT and the reference subjects, and differences between the two 
groups were most pronounced for the question about “problems in the 
urinary tract”, for which the relative risk was 1.4 (95% CI 1.2–1.7) for 
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the SRT group compared to the reference group. Severe symptoms in 
the urinary tract (i.e., a response of 4 or 5 [the maximum grade]) to at 
least one of the questions regarding urinary symptoms were reported 
by 16% in the SRT group and 9% in the reference group. Those levels 
are not negligible, and to some extent it is surprising that one in 10 of 
the men treated with RP only had such intense symptoms. The 
question concerning incontinence, an aspect that is very important to 
the patient, did not reveal any particular difference between the groups, 
which agrees with other studies [77,106]. The question about 
incontinence is also difficult to address if no pre-RT treatment 
evaluations have been performed [75], because the patients have 
undergone surgery that often affects the continence. The same 
objection about a lack of pretreatment symptom evaluation can be 
raised regarding sexual function. No results in our study indicated that 
SRT leads to deterioration of sexual function, but, inasmuch as all the 
investigated men had undergone RP, the evaluation would have to rely 
solely on the comparison of the two groups[65,76]. 
Raziee et al. [22] described the side-effects of PRT as tolerable and 
considered this treatment as underutilized based on the knowledge that 
side effects do not occur to an extent that would suggest not 
recommending PRT to the patient. There are fewer reports on severe 
symptoms after PRT that necessitate surgical interventions, with the 
exception of studies by Wallis et al. and Showalter et al. [89,90], and 
therefore we wanted to further investigate the incidence of serious side 
effects of such treatment in the long-term perspective in our own 
region/country. As outlined in Paper III, we conducted a register-based 
nationwide study to compare two matched groups of men, one treated 
with RP only (designated non-exposed) and the other with RP+RT 
(designated exposed), over a maximum follow-up period of 15 years 
after the RT. As our source of information, we used the PCBaSe, 
which is a highly reliable national database that has given rise to many 
studies[107-109]. Our analysis showed that the risk of having surgical 
interventions was increased in the urinary tract but not in the rectal 
tract in the exposed group as compared to the non-exposed group. 
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Interventions in the urinary tract were almost six times more frequently 
performed in the exposed group and was predominantly represented by 
bladder neck repair and urethrotomy. This observation agrees with the 
findings of Wallis et al. [90] showing that the complication rate 
following urinary tract procedures was higher for patients treated with 
RP+RT than for both those given RT only and those with RP only. We 
also found that the risk of undergoing interventions in the urinary tract 
steadily increased during the 15 years of follow-up time. The risk         
related to undergoing urinary diversion with or without cystectomy 
was four times more common in the exposed group, and we wanted to 
determine whether this intervention is related to the increased risk of 
bladder cancer (discussed further below). We found no such increased 
relationship between bladder cancer and cystectomy in the exposed 
group, in which only 15% had a bladder cancer diagnosis prior to 
cystectomy, whereas the corresponding rate in the non-exposed group 
was 71%. One conclusion that can be drawn from this finding is that 
the risk of undergoing urinary diversion after RP+RT is mainly 
increased by urinary tract complications after RT and not by the 
development of bladder cancer. Moreover, as described by other 
researchers as well [94,99], there is an increased risk of bladder cancer 
after RT, however based on our findings we believe that the bladder 
cancer mainly is of superficial origin since not necessarily treated with 
cystectomy, which would have been the fact if it had been muscle 
invasive. 
In our study, there was no clear difference in incidence of rectal 
procedures between the groups, although there was an increased risk of 
rectal interventions during the first 10 years in the exposed group, with 
a peak at 4–7 years according to the Kaplan-Meier graph. These events 
might have remained undetected, if a follow-up time shorter than 5–7 
years had been implemented. As reported by us and other investigators 
[84], rectal bleeding is a common side effect after RT for PC and is 
usually described as mild, and therefore the interventions we found 
probably represented more severe rectal bleeding (grade 3/4 according 
to RTOG/EORTC) that required local and presumably hemostatic 
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endoscopic treatment. This deduction is supported by our earlier 
finding that the rectal bleeding diminishes over time, as indicated by 
the observation that the incidence of surgical interventions in the rectal 
tract reached a peak in the RT group and then returned to about the 
same level as in the non-exposed group. Considering the overall cause 
of mortality, the higher rate in the exposed group in Paper III might be 
explained by more advanced PC in these patients. The PC mortality 
was nearly six times higher in the exposed group, but death due to non-
prostate cancer was similar in the two groups and was not affected by 
age (i.e., being younger or older than 70 years). Bolla et al. [23] have 
described a relationship with higher overall mortality for men aged 
> 70 years at the time of RT, which could not be confirmed in our 
study. However, these two investigations differ in certain aspects, and 
thus it is necessary to be cautious about drawing conclusions. One 
disparity compared to our study is that Bolla and colleagues did not 
clarify to what extent ADT was administered to the patients they 
evaluated. ADT has severe side effects, such as metabolic syndrome 
and cardiovascular incidents [28,110], which can potentially influence 
mortality. In our assessment, censoring from the time of ADT start was 
possible, and the analysis could be performed both with and without 
censoring for ADT, but we found no differences in PC deaths between 
these two possibilities. Accordingly, our study provided no results to 
support the assumption that PRT has a detrimental effect on health that 
can lead to shorter survival. 
We also investigated differences in development of secondary 
malignancies between the two groups in our study, and we found a 
more than twofold increase in the risk of developing bladder cancer in 
the exposed group. Such an elevated risk after PRT has also been 
described by other authors [99], although most reports have concerned 
primary RT and are therefore not directly applicable to PRT. In our 
study, the risk of bladder cancer in the exposed group increased 
steadily from 3 years after RT compared to the risk in the non-exposed 
group. However, the risk of rectal cancer did not differ between the 
exposed and the non-exposed group, and was actually almost identical 
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in the two groups after 15 years of follow-up. The development of 
secondary malignancies is probably influenced by dose-response 
factors, age, smoking habits, and length of follow-up, and needs to be 
further investigated, especially considering that younger men 
diagnosed with PC require treatment [111]. 
Part of the present research focused on the radiation treatment for PC 
and the concerns about the risk of side effects of treatment related to 
preparations, positioning, and matching procedures. Thus, in the 
second study (Paper II), we analyzed the dose distribution of SRT and 
the self-reported rectal bleeding of participants in the PROM survey 
(described in Paper I) who were, in majority, treated with the 3DCRT 
technique. We continued our evaluation by determining a possible 
relationship between the dose absorbed in the rectum and the PROM-
reported rectal bleeding; a dose-response relationship. To our 
knowledge, this has not been done previously in the postoperative 
setting, although many studies have focused on quantifying a 
relationship between reported rectal bleeding and rectal dose 
relationships between the objective RTOG/EORTC scales [83,112]. In 
light of that, and considering the ongoing technical development in the 
field of RT, we decided to apply our dose-response relationship for the 
3DCRT technique to estimate the risk for rectal bleeding for patients 
treated with VMAT. The observed prevalence of rectal bleeding to any 
extent was 22% in the 3DCRT group, and use of this estimated dose-
response relationship resulted in an estimated risk of 14% in the 
VMAT group. Thus, theoretically, the VMAT approach has the 
potential to decrease the prevalence of rectal bleeding. When 
comparing the treatment implementation there were differences in 
treatment volumes between the 3DCRT and VMAT methods, since a 
new delineation guideline was introduced at our department around 
2015, which resulted in larger target volumes in subsequent VMAT 
patients. Still, the rectal volume was essentially the same in the two 
treatment groups, and the calculated risk reduction remained, even 
though there were differences in target definition with larger PTV 
volumes in the VMAT group. 
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RT-induced rectal toxicity depends on the dose delivered, which in 
turn depends on the dose distribution technique, as well as the set-up, 
positioning, and matching accuracy. Inasmuch as the rectum exhibits 
daily variation in volume and consequently also in location [59,113],            
different doses per fraction can be absorbed over a long treatment 
period. Accordingly, the rectal wall mucosa, which is the origin of the 
bleeding, is exposed to varying doses of radiation. With a modern RT 
technique, such as IMRT or VMAT, the sparing of the rectal wall, and 
mucosa, may not be as successful as expected, because that the mucosa 
is located in such close proximity to the PTV, and the dose constraints 
for rectum are based on the entire rectal volume. Gomez et al. [114] 
investigated the difference between contouring the whole rectal 
volume and the rectal wall in IMRT treatment of primary PC, and they 
found that the relative volume of the rectal wall that was irradiated was 
larger than the corresponding whole rectal volume. Consequently, a 
thorough positioning and matching procedure is recommended to as far 
as possible avoid rectal toxicity, and this should preferably be 
accomplished by use of a CBCT that allows alignment to the bladder 
and rectum [31], the organs that are nearest, part of, the target. Both 
treatment groups in our study (paper II) were positioned according to 
bony anatomy by orthogonal kV imaging, which we perceive as an 
aspect that can be improved. Further research needs to be conducted to 
bring clarity regarding the significance of positioning in PRT and its 
correlation with patient reported toxicity. In addition, there is a strong 
connection between the volume and the location of the rectum and the 
bladder. A voluminous rectum pushes the bladder ventrally and 
superiorly and thus primarily affects the upper area of the target, and it 
can be considered to have some influence on the PTV. The bladder 
volume and location are of importance in the treatment, both to 
achieve delivery of the correct dose to the cancer cells and to spare the 
surrounding tissue. This is one reason for performing bladder 
preparations meaning bladder filling protocols, an approach that is 
generally accepted and employed in RT for PC [53]. Also, there are 
many different filling protocols that stipulate volumes varying from an 
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empty to a full bladder [54,115]. In our study, Paper IV, we compared 
two different bladder filling protocols regarding their effect on bladder 
filling and compliance, and we found that neither of these strategies 
could fulfill the intention of a constant bladder volume during the 
treatment sessions. The measurements of volume and bladder 
extension distance were accomplished through a weekly CBCT from 
which volumes and measured distances were extracted. Variations in 
volume were seen in both groups, both within each patient, between 
patients, and between groups. With increasing volume, the bladder 
extended cranially, but the caudal position of the bladder seemed fixed, 
that is, it did not change with variation in bladder volume. Inasmuch as 
the target always includes the inferior part of the bladder, the fixed 
inferior part allows one static matching point when the superior part of 
the bladder undergoes changes in volume and positioning. The 
positioning and matching in PRT constitute a challenging issue that 
includes a PTV consisting of the bladder and its environment and the 
variable rectum in the vicinity. The concept of positioning and 
matching through CBCT that has been proposed by some authors 
seems adequate for future use [116].                                                     
The objective of trying to maintain a constant bladder volume, 
preferably full or half full, is assumed to reduce the development of 
side effects. This includes side effects in the small intestine, which is 
pushed away from the treatment region, and also the superior part of 
the bladder, which is not included in the PTV region [117]. Moore et 
al. [118] conducted a retrospective dosimetry study and observed that 
150 ml in bladder volume in primary radiation for PC was a threshold 
that should be observed to avoid violating the constraint dose to the 
bladder specified in the dose plan, even though the bladder volume at 
pCT was larger. Another reflection is that, in women with cervical 
cancer, it is often recommended that treatment be performed with an 
empty bladder, and there are reports indicating better reproducibility 
when maintaining an empty bladder [119]. It is evident that a great 
deal remains to be investigated regarding the effect of different bladder 
volumes on the development of side effects in the urinary tract after 
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PRT for PC. The dose-response relationship is not clear and is often 
based on primary radiation, and reports on hot spot theories have 
proposed it is more likely that the dose to the trigone and bladder neck 
is involved in appearance of side effects [80,81]. Still, these regions 
will unavoidably always have to be part of the CTV and receive the 
full treatment dose. Our second aim in paper IV was to evaluate how 
changes in bladder filling could affect the CTV and its coverage. Since 
95% dose coverage is a dose criterium for the PTV and includes the 
caudal part of the bladder, we examined the correlation between the 
V95%bladder and the total bladder volume, to evaluate if the variation in 
bladder volume could interfere with the localization of the target. We 
compared the increase in V95%bladder as the result of the increase in total 
bladder volume and found no appreciable dependence between those 
two aspects suggesting a minimal change in CTV coverage. Though, 
this proposal is only applicable if the EORTC delineation guideline is 
adopted since it has a smaller bladder volume included in CTV 
compared to other delineation guidelines.                                         
From a patient perspective, there was somewhat limited compliance 
with the bladder filling protocol, which presumably reflects the 
patients’ real-life situation. The treatment period was long, and many 
patients met each other in the waiting room at the facility or on the bus 
during the ride to the clinic. Therefore, we assumed that the patients 
influenced each other with respect to how to manage fluid intake and 
voiding before treatment, and such bias is difficult to control. Fluid 
intake and voiding according to a special schedule can also influence 
the patients by creating a feeling that inadequate compliance with the 
protocol instructions might affect the possibility of being cured. The 
same apprehension can be a problem at treatment set-up, when the 
patient is anxious and has problems relaxing on the examination table. 
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In summary 
In the four studies included in the present research, we have obtained 
information on the extent to which late side effects appear after PRT, 
both as reported by patients and as revealed by retrospective database 
evaluations. The finding of a higher incidence of surgical interventions 
in the urinary tract that increased steadily over time in the PRT group 
is both serious and convincing. Notwithstanding, it seems doubtful that 
strategies will emerge that can help us avoid the need for such 
interventions, because the radiation energy in PRT must be delivered 
to the inferior part of the bladder and sphincter area, the locations 
where the injuries originally appear. However, these results should 
compel us to be very cautious when recommending PRT to patients 
with a history of postoperative bladder neck strictures. On the other 
hand, we believe that there are strategies that can potentially diminish 
the development of side effects in the rectum, e.g., rectal bleeding. For 
example, the choice of treatment technique can be part of an 
improvement, and a more appropriately planned positioning and 
matching procedure would provide even better results. 
Postoperative radiation therapy in PC is still a treatment alternative for 
carefully selected patients based on our regional and national findings. 
However, each patient should be counseled regarding the scenario of 
risks that exist in relation to the possibility of cure. 
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6 CONCLUSIONS 
 
Paper I  
There were small differences between the groups when evaluating the 
PROM responses in a long follow-up time perspective, in median 6.7 
years after SRT and 10 years after RP. Still, there was a subset of men 
in the SRT group that developed more severe side effects, as rectal 
bleeding, and from this finding arises a challenge to develop a better 
implementation of the treatment technique. 
 
Paper II 
In this study we could identify a dose-response relationship between 
rectal dose distribution and the risk of self-reported rectal bleeding in a 
long-term perspective for men treated with 3DCRT. From these 
calculations we could estimate an average risk of rectal bleeding for a 
contemporary cohort of patients treated with VMAT as being lower 
than the risk in the 3DCRT group. 
 
Paper III 
Evaluation of severe, treatment demanding, side effects after PRT in 
prostate cancer, in a 15-year follow-up perspective, revealed small 
differences between the groups according to surgical interventions in 
the rectal tract, overall mortality and development of secondary 
malignancies in the rectum. However, we found a six folded increased 
risk of interventions in the urinary tract, steadily increasing, and a 
doubled risk of developing bladder cancer when comparing the groups. 
Still, in absolute figures the cumulative incidence is low. 
 
Paper IV 
We found no differences between the two bladder protocols studied in 
ability to maintain a constant bladder volume during the treatment 
period. Furthermore, we could not find that changes in bladder volume 
interfered with the localization of the CTV. 
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7 FUTURE PERSPECTIVES 
To continue the work on optimization of PRT in prostate cancer new 
areas of research has appeared, usually at the time of investigating the 
results of the ongoing studies. 
Hence, further research in this, the PRT field, has been planned and 
started. To be able to better understand the extension and possible 
delineation of the postoperative fossa a pilot study has been initiated. 
We hypothesize that the marking of the surgical area during surgery 
with gold markers, would make it possible to reproduce the current 
area if/when postoperative radiation therapy is imminent. Seven 
patients have been included in this trial so far and the procedure is to 
perform a MRT prior to the surgical procedure, RALP. During surgery 
5 gold markers (Gold Anchor®) are positioned at: top of vesicles, mid 
position of bladder neck and laterally, mid-prostate, towards pelvic 
wall, in the same laparoscopic way as the surgery is performed. Three 
months after surgery a new MRT is performed and an evaluation of the 
prior prostatic fossa is made from the MRT images. The postoperative 
prostatic fossa or bed, will be evaluated and compared to, both the 
prior prostate size and site, and to the existing delineation guidelines 
for PRT.  This could lead to better understanding and validation of 
existing guidelines and possibly propose changes in future delineation 
techniques. Until now we have evaluated the method according to best 
placement of fiducial markers, and to what MRT protocol will best fit 
to analyze the images, addressing this question. 
 
Another ongoing, but temporarily postponed, study is focused on 
evaluating the variation in rectal volume during the 35 treatment days 
in PRT. We found large variations in rectal volume in the earlier 
described, bladder filling study. In short, there were both inter- and 
intra-individual differences in extension of the rectum in an 
anteroposterior direction between different days during the treatment 
period, in some cases as much as 4 cm for the same patient where both 
the bladder and the rectum were delineated on the weekly CBCT 
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images. The hypothesis is that these daily changes in volume and 
extension of rectum may lead to underdosage of the target and 
overdosage of organs at risk. In this study, a CBCT is performed on 
each treatment day, and the original dose plan is then transferred to the 
CBCT image in which the CTV, PTV, and OaR are re-delineated. A 
new dose distribution analysis can be conducted, and a summary plan 
for doses actually delivered to participating volumes can be calculated. 
Consequently, we will be aware of variations in the rectal wall and 
thereby be able to consider whether, and probably how, positioning 
and matching should be modified.  
To evaluate the side effects we will use the PROM evaluation form 
that is distributed to all patients before treatment start and then after 3, 
12 and 36 months. The results of this PROM survey can then be 
compared to the earlier PROM-evaluation from the 3DCRT series 
(paper I).
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